KODIAK SCIENCES INC

Kodiak Sciences CFO Buys 66,500 Zero‑Price Options, Betting Big on Next‑Gen Biotech Milestones

Inside Kodiak’s July 15 option purchase: CFO John Borgeson buys 66,500 rights amid strong earnings and clinical milestones, signaling bullish insider confidence.

DirectorDealingsBot

17/07/2026, 22:56

3 minutes to read

CFO John Borgeson Executes Structured 10‑b‑5‑1 Trading Plan, Buying at $1.04 While Selling at $34, Signaling Long‑Term Confidence Amid Kodiak Sciences’ Volatile Stock Journey

Insightful insider trading analysis shows CFO John Borgeson’s strategic buys at $1.04 and disciplined sales at $34‑plus, signaling confidence and liquidity plans for Kodiak Sciences.

DirectorDealingsBot

06/06/2026, 00:12

3 minutes to read

Kodiak CFO Switches Gears: Buys 28,614 Shares After Daily Sell‑Off, Hinting at Insider Confidence in Biopharma Pivot.

See why Kodiak Sciences’ CFO’s buy‑the‑dip move may signal long‑term confidence in the company’s retinal‑disease pipeline.

DirectorDealingsBot

16/04/2026, 23:16

3 minutes to read

CFO of Kodiak Sciences Buys 30,000 Shares at 1/3 of Market Price, Sending Shockwaves Through Insider Trading News Flash

Insider CFO buys Kodiak Sciences shares at a steep discount, hinting at strong confidence in the biotech’s clinical pipeline and long‑term upside.

DirectorDealingsBot

03/04/2026, 02:42

3 minutes to read

Kodiak Sciences CEO Victor Perlroth Buys 300,000 Shares at $1.04, Sparking Investor Optimism Ahead of Zenkuda FDA Submission.

CEO Victor Perlroth’s fresh 300k‑share buy at $1.04 boosts Kodiak Sciences’ Phase III Zenkuda hype—signaling confidence, potential upside, and a bullish market outlook.

DirectorDealingsBot

27/03/2026, 23:24

3 minutes to read